Licensing & partnerships
40 articles
Lilly bets on Metis's AI platform for tissue-targeted lipid nanoparticles
- Eli Lilly and Hong Kong-listed METiS TechBio agreed a collaboration worth up to about $1.1 billion to develop tissue-specific delivery technologies.
- METiS contributes its AiLNP platform for ionizable lipid discovery, combining a large lipid library, screening and a lipid language model.
- Metis gets a low double-digit-million upfront, plus development, regulatory and commercial milestones and single-digit tiered royalties; no candidates or indications were named.
The headline figure is almost all contingent, so the real signal is the low-eight-figure upfront: Lilly is buying an option on delivery chemistry, not an asset. Extra-hepatic LNP targeting is the bottleneck for genetic medicines, and Lilly keeps stacking deals around it. For competitors in LNP design, the question is whether AI-generated lipid libraries can show reproducible tissue selectivity in vivo.
Lilly partners with Hong Kong's Metis in $1.1B deal to bolster AI nanoparticle discovery ↗
Roche and Hansoh sign a second, much larger ADC collaboration
- Roche and China's Hansoh signed a collaboration on a portfolio of early-stage antibody-drug conjugates, its second ADC deal after a 2025 CDH17 ADC license.
- Reports put the upfront at about $400 million plus a further $110 million after a year, with total potential payments above $15 billion and royalties.
- Hansoh leads early development through global phase 1a, after which Roche takes over development outside Greater China.
The structure is the story: a platform-style deal where the licensor runs the work through phase 1a looks like Roche buying options on China's early ADC output rather than a single asset. A headline above $15 billion is mostly back-end milestones, so the real signal is a near-$500 million near-term cash commitment. It also keeps Roche in the race with Merck, Pfizer and AstraZeneca for Chinese ADC supply.
Licensing galore: Roche ties up with Hansoh on ADCs as Rani rounds out week with Chugai pact ↗
Lilly roughly doubles its Gate Bioscience Sec61 pact, to up to $870M
- Lilly expanded its collaboration with Gate Bioscience to a potential value of up to $870M, from the original 2025 pact worth up to $856M.
- The expansion adds one target, with an option on a second; Gate gets an upfront payment, further payment if a second target is chosen, research funding and milestones.
- Gate's platform works on Sec61, the channel through which secreted and membrane proteins exit the cell; targets and indications are undisclosed.
An expansion rather than a new deal is the real signal: Lilly saw enough from the first target to pay for another. With Pfizer following into Sec61 with Enodia a week later, a small-molecule channel-modulation approach to 'undruggable' secreted proteins is turning into a crowded field. Undisclosed upfront and targets make the economics hard to judge.
Gate CEO sees expanded $870M Lilly pact as 'vote of confidence' ↗
AstraZeneca pays insitro $40M upfront for AI-driven liver and heart target discovery
- AstraZeneca and insitro signed a collaboration to find novel drug targets for liver and heart diseases using AI.
- Reported terms: a modest upfront payment of $40 million, with milestones taking the total to about $1.5 billion.
- Terms come from search-snippet reporting of the Fierce Biotech article, which could not be opened directly.
A small upfront against a large biobucks headline is the standard shape for platform-style target discovery: AstraZeneca pays for optionality, not assets. The partner choice shows where AZ sees the pharmacology bottleneck, in picking targets rather than designing molecules. I'd read it as another hedge alongside its other AI deals; the payoff comes only if the targets are credible.
AstraZeneca inks $1.5B insitro deal for AI-enabled target discovery of liver, heart disease drugs ↗
Gilead licenses three dual-masked T-cell engagers from Vir in a deal worth up to about $1.9B
- Vir will discover, design and optimize three T-cell engagers against solid-tumor antigens on its dual-masked PRO-XTEN platform; Gilead holds exclusive rights to nominate candidates and then develops and commercializes them.
- Vir receives $90M up front ($65M cash plus a $25M equity investment) and $45M in near-term preclinical milestones.
- Up to $1.74B in development, regulatory and commercial milestones and tiered royalties could follow.
This is Gilead's third T-cell engager move in a short stretch (Merus, Ouro, now Vir), so the oncology thesis is clearly masked, conditional-activation TCEs for solid tumors. For Vir, it's the second platform deal this year and non-dilutive cash that lets it fund its own pipeline; the equity premium shows Gilead's commitment. Preclinical risk stays high.
Vir CEO sees ‘opportunity to do more deals’ after striking $1.9B Gilead pact for dual-masked TCEs ↗
Zealand pays $30M upfront for Generate's AI-designed multispecific proteins in obesity
- Generate will use its AI platform to design multispecific proteins for obesity and metabolic disease, leading research to lead-candidate selection.
- Zealand then takes over clinical development, regulatory work and commercialization, starting with two programs and an option on a third.
- Reported terms: $30M upfront, up to $35M of early preclinical milestones and nearly $1.2B in total milestones plus tiered royalties.
Zealand already has Roche and Boehringer on its obesity assets, and this adds a third modality bet, AI-designed biologics, with a small upfront. The structure keeps risk on Generate until a lead exists. For Generate, it's another big-pharma-style validation after Novartis and Amgen, although multispecifics in obesity are still unproven clinically.
Zealand inks $1.2B Generate pact to add multispecific proteins to obesity pipeline ↗
Pfizer partners with Enodia on Sec61 inhibitors in a deal worth over $500M
- Enodia will use its platform to find and develop Sec61 inhibitors against several targets; Pfizer takes on clinical, manufacturing, regulatory and commercial work.
- The upfront is undisclosed; R&D and sales milestones could push the total above $500M, with tiered royalties on top.
- It follows Lilly's deal with Gate Bioscience in the same Sec61 space, reportedly worth about $870M.
Sec61 is a hard target: it is a core translocon, and the chemistry has to block only disease-linked proteins without general toxicity. Two big pharmas moving within a week suggests selectivity data are persuasive behind closed doors, but the undisclosed upfront and targets mean the real signal is still thin. Watch which client proteins each company is going after.
Pfizer pens $500M Enodia pact to join Lilly in emerging protein degrader field ↗
Roche licenses Rona's ALK7-targeting RNAi obesity candidate in a deal worth up to $1.16B
- Roche gets an exclusive license to Rona Therapeutics' investigational ALK7-targeting RNAi candidate for obesity.
- Terms: up to $100M in upfront and near-term milestones, plus up to $1.06B in longer-term milestones and tiered royalties.
- The program's codename and development stage were not disclosed.
ALK7 is the second hot RNAi obesity target after GSK's earlier SiranBio deal, and Roche says it wants to be a top-three obesity player, so this is portfolio-building on the cheap: small upfront, back-loaded milestones. It's also Roche's fifth deal with a Chinese drugmaker since late August, a sign that the best-priced early assets are still found there.
Roche inks $1.2B deal with China's Rona to enter emerging ALK7 obesity race ↗
Roche signs molecular glue discovery deal with China's Defand Therapeutics
- STAT reports Roche has signed a drug discovery deal with Chinese biotech Defand Therapeutics focused on molecular glue medicines.
- Only the public lede of the STAT+ article could be read, so financial terms and targets are unverified here.
Roche keeps adding molecular glue partners rather than betting on one platform, and sourcing from Chinese biotechs fits the wider licensing trend. Without upfront and milestone figures I'd treat this as a discovery-stage option play, with the real signal being which targets and how many are named.
STAT+: Roche inks drug discovery deal with Chinese biotech, focused on molecular glue medicines ↗
Genentech pays Alector $100M upfront for brain-penetrant GCase therapy AL050
- Alector licensed AL050, a preclinical brain-penetrant engineered GCase enzyme replacement therapy for Parkinson's disease, to Genentech.
- The deal brings $100M upfront, up to $1.17B in milestones and tiered royalties; Genentech takes development, manufacturing and commercialization.
- Alector keeps its Brain Carrier platform, and the cash extends its runway into 2029.
A $100M upfront for a preclinical asset shows how much Roche values a validated blood-brain barrier shuttle in GBA1-linked Parkinson's. For Alector, it's a lifeline that funds its Alzheimer's and siRNA programs. The risk is that delivery, not the enzyme, is the real bet, and Genentech has other shuttle options.
Genentech pays Alector $100M for preclinical Parkinson's prospect ↗
Merck pays $400M upfront for SciBrunch's preclinical KRAS G12D inhibitor
- Merck took exclusive worldwide rights to SPR2015, an oral preclinical KRAS G12D (ON) inhibitor from Shanghai-based SciBrunch.
- SciBrunch gets $400M upfront, with total potential value of $2.13B across milestones.
- The deal has already closed.
$400M upfront for a preclinical asset is striking and shows how heated the KRAS G12D race has become, with China-originated assets now priced like clinical ones. For Merck it's a late entry into a field where it needs a differentiated ON-state profile, and the one to watch is first-in-human data.
CSL pays $355M upfront to co-develop Alentis' anti-Claudin-1 antibody lixudebart
- CSL will pay $355 million upfront, plus up to $1.2 billion in commercial milestones, to co-develop and co-commercialize the anti-Claudin-1 antibody lixudebart.
- Profits split 55% CSL and 45% Alentis; CSL funds the ongoing phase 2 in ANCA-associated vasculitis with rapidly progressive glomerulonephritis and a phase 3.
- Phase 2 studies in focal segmental glomerulosclerosis and primary sclerosing cholangitis are also planned.
A 55/45 profit split with a $355M upfront is unusually rich for a phase 2 asset, and it tells me CSL wants a nephrology franchise on real terms. Alentis keeps a meaningful economic stake instead of a royalty. The multi-indication plan across kidney and liver is the bet: one Claudin-1 mechanism, several fibrotic diseases.
CSL pays $355M to co-develop Alentis' phase 2-stage fibrosis drug ↗
JCR grants Italfarmaco US, EU and Latin America rights to Hunter syndrome drug JR-141
- JCR Pharmaceuticals signed an exclusive license with Italfarmaco for JR-141 (pabinafusp alfa; Izcargo in Japan) in the US, Europe and Latin America.
- The blood-brain-barrier-penetrating enzyme replacement therapy targets Hunter syndrome (MPS II); it was launched in Japan in 2021 and is in Phase 3.
- Italfarmaco will commercialize after approvals; JCR keeps manufacturing and receives upfront, milestone, royalty and supply revenue. Amounts were not disclosed.
Undisclosed economics make this a structure story, not a price story. JCR hands Italfarmaco commercialization in the US, Europe and Latin America but keeps manufacturing and supply revenue, which preserves margin on a complex biologic. For Italfarmaco it is a rare-disease pipeline add; what I would want to see is Phase 3 data and regulatory timelines before judging value.
第一三共「ダトロウェイ」併用療法開発で米サミットと提携／JCRファーマ「イズカーゴ」欧米販売でライセンス契約 など｜製薬業界きょうのニュースまとめ読み（2026年10月2日） ↗
Summit, AstraZeneca and Daiichi Sankyo to test ivonescimab plus Datroway, starting with Phase III in 1L TNBC
- Summit, AstraZeneca and Daiichi Sankyo announced a clinical collaboration combining ivonescimab (PD-1xVEGF bispecific) with Datroway (datopotamab deruxtecan, a TROP2-directed ADC).
- It starts with a Phase III study in first-line triple-negative breast cancer, with plans to expand to other settings including lung cancer.
- The companies will share trial costs, and each retains development and commercial rights to its own drug.
Three companies, two assets, and no one gives up rights: this is a cost-sharing structure, not a licensing deal. For Summit, pairing ivonescimab with a validated TROP2 ADC borrows AstraZeneca and Daiichi's TNBC credibility and trial muscle. For the big partners, it is a cheap hedge on the PD-1xVEGF class. I would want to see the control arm and endpoints before judging how much it de-risks.
Summit partners with AstraZeneca and Daiichi; Eccogene earns $50M milestone ↗
Novo bets up to $1.4B on Orbis's oral macrocycle platform
- Orbis Medicines signed a multi-target discovery and license deal with Novo Nordisk worth up to $1.4B in upfront and milestone payments plus tiered royalties.
- Novo also takes a strategic equity stake in the private Copenhagen company; this is Orbis's first pharma partnership.
- The work uses Orbis's AI-enabled nGen platform to make macrocycles aimed at turning injectable cardiometabolic therapies into orals.
- Orbis reported preclinical oral bioavailability up to 18%; targets and disease areas beyond cardiometabolic were not disclosed.
This is Novo hedging its oral strategy beyond small-molecule GLP-1s and oral semaglutide: macrocycles are the bet that peptide-like potency can survive the gut. The headline number is mostly milestones, so the real signal is the equity stake and a multi-target structure that lets Novo test the platform cheaply. Lilly is also an Orbis backer, which tells you both obesity leaders want the same oral-peptide option.
Lilly-backed Orbis does up to $1.4B macrocycle deal with Novo ↗
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease
- Novartis gains worldwide exclusive rights to ABO2203, an mRNA-encoded CD19xCD3 T-cell engager produced in vivo to reset B cells in autoimmune disease.
- The package is $575M upfront plus up to $7.2B in milestones (up to $7.8B in total) and royalties.
- Novartis also receives options on other Abogen RNA-based programs.
- The deal follows Novartis pausing an autoimmune CAR-T program after three deaths.
The $7.8B headline is mostly contingent; the $575M upfront is the real conviction signal. Landing this after pausing an autoimmune CAR-T program reads like Novartis hedging its B-cell reset thesis toward an in vivo, mRNA-delivered CD19xCD3 format. The options on other Abogen RNA programs suggest it is buying platform access, not just one asset.
Novartis pens $7.8B deal for Abogen's in vivo autoimmune T-cell engager ↗
Sanofi Pays Regeneron $1B Upfront to Add Four Long-Acting Immunology Antibodies to the Dupixent Alliance
- Sanofi and Regeneron expanded their alliance with $1 billion upfront and up to $7 billion in development, regulatory and commercial milestones.
- The deal adds four antibodies: clinical-stage long-acting IL-13 REGN20423, a long-acting IL-4xIL-13 bispecific and two preclinical long-acting antibodies against IL-4 pathway targets.
- Regeneron leads R&D, Sanofi leads global commercialization, and costs and profits split 50:50.
This is Sanofi buying a Dupixent successor from the one partner that already knows how to make that franchise work, ahead of the 2031 US patent expiry. Paying $1B for a Phase 1 antibody and three preclinical ones is really a bet on long-acting dosing as the differentiator against a crowded type 2 inflammation field. For Regeneron it is non-dilutive funding plus a reconfirmed partner; I'd watch whether Sanofi's other immunology assets get de-prioritized.
Sanofi pays Dupixent partner Regeneron $1B upfront for 4 early-stage assets to ignite R&D ↗
Novo Pays $300M Upfront for Hengrui's Weekly Oral GLP-1/GIP Agonist
- Novo gets exclusive rights outside mainland China, Hong Kong, Macau and Taiwan to HRS-1596, a once-weekly oral GLP-1/GIP dual agonist, for $300M upfront and up to $2.3B in milestones plus royalties.
- The asset is Phase 1-ready, with Chinese clearance to start trials in weight management and type 2 diabetes; closing is expected in Q4 2026.
Paying $300M upfront for a molecule that hasn't dosed a human outside China shows how badly Novo wants an oral follow-on while Lilly presses its lead. It also fits a pattern of buying de-risked-enough optionality from outside rather than building it, after smaller deals like Nanexa. Weekly oral bioavailability is the real technical risk, and the milestone-heavy structure shields Novo if it fails.
Novo to spend $300M upfront to license Hengrui's weekly oral weight loss drug ↗
AstraZeneca Takes a $2B Stake in Summit to Pair Ivonescimab with Its ADCs
- AstraZeneca is buying $2B of convertible preferred stock, giving it about 12% of Summit's common stock (about 10.6% fully diluted).
- The first combination pairs Summit's PD-1xVEGF bispecific ivonescimab with AstraZeneca's CLDN18.2-directed ADC in gastrointestinal cancers; a memorandum of understanding covers a broader program with more AstraZeneca ADCs.
This is AstraZeneca buying a seat rather than a pipeline: equity plus combination rights instead of an acquisition or license, keeping it close to a PD-1xVEGF class it doesn't own without paying for the asset outright. The bet is that ADC plus PD-1xVEGF combinations become a next oncology backbone, with AstraZeneca's ADC portfolio as the partner of choice. The broader MOU is non-binding, so definitive terms are the thing to watch.
AstraZeneca scales Summit's PD-1xVEGF strategy with $2B investment to fuel ADC combinations ↗
Tolerance Bio Adds Tanabe’s Anti-IL-33 Antibody in Deal Worth Up to $560M
- Tolerance Bio takes global development rights and ex-Japan commercial rights to Tanabe Pharma's clinical-stage anti-IL-33 antibody MT-2990, renamed TLB-33, in a deal with milestones that could reach $560 million.
- The antibody has been tested in more than 150 patients across five trials; Tolerance plans a Phase 2 study on preserving thymic function and immune resilience.
Second thymus-themed in-license in a month: Tolerance is assembling a pipeline around one biological thesis using de-risked clinical assets rather than its own discovery. That is capital-efficient, but it means the company's value rests on the thymus hypothesis being right, not on any single molecule. Pharma sellers get a clean exit for a deprioritized antibody, the usual pattern for mid-stage assets.
Tolerance continues thymus-focused deals with $560M pact for Tanabe's… ↗
Genentech Pays $55M Upfront for Earendil’s AI-Built Oncology Bispecifics
- Genentech will pay Earendil Labs $55 million upfront, with up to about $1.445 billion in development, regulatory and sales milestones, plus tiered royalties.
- Earendil leads antibody discovery and early clinical work on pre-agreed target pairs using its AI antibody-generation platform; Genentech takes over global development and commercialization.
Roche is buying optionality on target combinations, not a single asset: a small upfront against a milestone-heavy tail is the classic platform structure, and it limits the downside if the AI-generated molecules disappoint. The signal is that big pharma still wants bispecific capacity in oncology after the PD-1×VEGF rush, and is willing to source it from AI-native shops.
Roche's Genentech inks $1.5B bispecific pact with fast-rising Earendil… ↗
Merck Licenses China-Origin KRAS G12D Inhibitor SPR2015 for $400M Upfront
- Merck & Co. entered an exclusive global license agreement with Shanghai-based SciBrunch Therapeutics for SPR2015, an investigational oral KRAS G12D molecular-glue inhibitor.
- SciBrunch will receive $400 million upfront, with total deal value up to $2.13 billion including milestone payments.
- The deal reflects a growing trend of U.S. pharma companies in-licensing China-originated oncology assets.
This plugs Merck's biggest KRAS gap: everyone's crowded into G12C, but G12D — more common in pancreatic and colorectal cancer — has stayed stubbornly undrugged with covalent chemistry. A molecular-glue approach, if it works, sidesteps that entirely. The modest 19% upfront-to-total ratio signals early-stage derisking, not a validated asset — expect Western rivals to scramble for the remaining China-origin G12D candidates.
Maruho and BMS Partner on Japan Sales for TYK2 Inhibitor Sotyktu
- Maruho and Bristol Myers Squibb (BMS) signed a Japan sales partnership for Sotyktu (deucravacitinib), BMS's oral TYK2 inhibitor, starting October 1, 2026.
- Maruho will handle domestic sales and distribution, promoting the drug in dermatology and rheumatology, while BMS continues promotion in rheumatology.
- Sotyktu is approved for plaque, pustular and erythrodermic psoriasis, with a psoriatic arthritis indication added in May 2026.
BMS ceding Japan commercial lead to Maruho is a tacit admission that dermatologist relationships beat global scale here — the classic foreign-innovator/domestic-specialist access play. Adding rheumatology promotion right after the May PsA nod signals urgency to outrun oral JAK rivals before positioning hardens. For Maruho, it's low-risk topline padding that fits its derm book without R&D exposure.
Novo Nordisk Taps Nanexa's Nanocoating Tech for Long-Acting Obesity Shots
- Novo Nordisk signed a global licensing deal with Swedish biotech Nanexa for its ALD-based PharmaShell platform, which coats drug particles to control release.
- Covers up to five programs in obesity, diabetes and cardiometabolic disease, aiming for monthly/quarterly dosing versus more frequent injections.
- Worth up to €1.165B, with ~€615M upfront/milestones plus royalties; Nanexa shares more than doubled.
Novo again chooses a capital-light platform bet over a big asset buy: licensing unproven ALD nanocoating across five programs to chase Lilly's once-monthly ambitions, since monthly dosing is what keeps patients on therapy once oral GLP-1s and biosimilars start undercutting Wegovy on convenience. Tellingly, ~€615M upfront/milestones against a €1.165B ceiling means Nanexa, not Novo, fronts most of the technical risk until PharmaShell proves out in humans.
Novo does another small deal, this time with drug delivery biotech Nanexa ↗
Roche Flu Drug Xofluza Cleared for Generic Production Under Pandemic-Prep Deal
- The Medicines Patent Pool signed sub-licensing deals with 11 generic manufacturers to produce Roche's flu antiviral Xofluza (baloxavir marboxil).
- The agreements, building on MPP's broader license with Roche, cover supply to roughly 129 low- and middle-income countries and include technical support for regulatory approval.
- They also carry pandemic-specific provisions meant to ease supply, territory and royalty constraints if a global flu outbreak occurs.
Roche is front-running compulsory-licensing pressure here, not waiting for a pandemic to force its hand the way COVID access fights forced others — cheap reputational insurance bought years early. But 11 sub-licensees on paper isn't surge capacity: without tech-transfer and validation runs now, that capacity stays theoretical until an outbreak tests it. Still, MPP's Xofluza network beats what Gilead ever built for oseltamivir — a real bar-raise on pandemic-prep licensing.
Licensing deals on generic versions of Roche flu drug aimed at preparing for pandemic ↗
Lilly Strikes Up to $3.35B Discovery Deal with China's InnoCare
- Eli Lilly signed a discovery-stage collaboration and licensing deal with Beijing-based InnoCare Pharma worth up to $3.35 billion.
- Terms include up to $100 million upfront, up to $3.25 billion in milestones, and royalties, as InnoCare hunts compounds against up to five undisclosed targets.
- It marks Lilly's fourth China-biotech deal since early 2025, after Insilico Medicine, Innovent Biologics and Haisco.
Fourth China-sourced discovery deal for Lilly since early 2025 — this is deliberate strategy, not opportunism: outsourcing early-target risk to lower-cost Chinese biotech engines. The $100M upfront against $3.35B total (~3%) is a cheap option on unproven targets, not a derisked buy. China's shifting from manufacturing base to discovery pipeline for Big Pharma.
In another China pact, Lilly makes a deal with InnoCare worth up to $3.35B ↗
Flagship Pioneering Lands Up to $47M Pentagon Contract for Biodefense Tech
- Flagship Pioneering has won a Department of War contract worth up to $47 million over five years to advance next-generation medical countermeasures against evolving biological threats.
- Named ONTARGET, it functions as a platform-technology evaluation rather than a single-product deal, letting officials assess offerings across Flagship's company network and add projects over time.
- Apriori Bio and Prologue Medicines, both Flagship-founded firms, are named as initial projects under the contract.
$47M over five years is trivial next to legacy BARDA-style awards — the real prize is structural: ONTARGET makes the Pentagon a standing customer for Flagship's whole venture pipeline, not one asset. That's a sourcing channel other VC-backed biotechs can't easily replicate, and a way to monetize portfolio companies like Apriori Bio and Prologue Medicines before they've proven commercial markets exist.
GSK Doubles Down on China-Sourced ADCs After Hansoh Deal Delivers Phase 3 Win
- In 2023, GSK paid about $270 million upfront for ex-China rights to two Hansoh Pharma antibody-drug conjugates targeting B7-H3 and B7-H4.
- The B7-H3 candidate has since posted an 18.5-month median overall-survival benefit in relapsed small-cell lung cancer, plus a progression-free-survival win in osteosarcoma.
- GSK plans to push the B7-H4 asset into five additional Phase 3 trials, reinforcing a dual in-house/China-sourced oncology pipeline strategy.
The $270M upfront now looks like a steal — a Phase 3 survival win in SCLC plus a PFS hit in osteosarcoma would command a far richer price today, which is exactly why AstraZeneca, Merck and Pfizer scrambled to strike their own China ADC deals. Five more B7-H4 Phase 3s isn't optionality — it's GSK committing real capital to a China-sourced pipeline, not hedging it.
GSK aiming to 'balance West and East' after Hansoh deal success showed China's potential ↗
Lexeo Expands Friedreich's Ataxia Pipeline With Mantle Buyout
- Lexeo Therapeutics agreed to acquire Mantle Therapeutics for up to $21.3 million, adding four frataxin-targeting Friedreich ataxia programs to its AAV gene therapy pipeline.
- Early data on the lead acquired asset in a small patient cohort showed a meaningful improvement on a standard ataxia rating scale.
- Lexeo also struck new research collaborations with Weill Cornell Medicine, Vivet Therapeutics, and Apertura Gene Therapy to pursue CNS-penetrant treatment approaches.
At $21.3M this is pocket change next to Telix-ITM, but strategically it's the smarter bolt-on: Lexeo already runs an AAV cardiac program in Friedreich's ataxia, so four more frataxin-targeting assets plus fresh CNS-penetrant collaborations with Weill Cornell, Vivet, and Apertura consolidate it as the depth player in a disease few large-caps are chasing.
Lexeo takes up the Mantle in $8M acquisition for Friedreich ataxia assets ↗
GSK licenses HUTCHMED's first-in-class KRAS-EGFR conjugate HMPL-A830 in deal worth up to $1.3B
- HUTCHMED and a GSK subsidiary signed an exclusive development and license agreement for HMPL-A830, described as a first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate (ATTC).
- HMPL-A830 pairs a highly selective, potent small-molecule KRAS inhibitor payload with an anti-EGFR antibody, delivering the inhibitor selectively to EGFR-expressing tumor cells while also blocking EGFR signaling.
- GSK gains worldwide development and commercialization rights excluding Mainland China, Hong Kong, Macau and Taiwan, which HUTCHMED retains.
- Deal terms: $110 million upfront, up to $1.295 billion in additional development, regulatory and commercial milestone payments, plus tiered royalties on net sales.
- HUTCHMED will conduct the global Phase 1 program, expected to start in H2 2026, after which GSK takes over subsequent clinical development and commercialization.
- Initial clinical development will focus on colorectal, pancreatic and lung cancers.
Another Western major fills its oncology pipeline via China-origination rather than in-house discovery — GSK joins a fast-growing queue of ADC/conjugate deals mining HUTCHMED's pipeline for de-risked-but-early assets. The math is telling: $110M upfront against a $1.295B ceiling is roughly 8.5% at signing — real conviction, heavily hedged, standard for a preclinical/Phase 1 asset where GSK is paying mostly for optionality until clinical data lands. The ATTC design — a small-molecule KRAS payload riding an EGFR antibody — is a genuinely differentiated angle in an overcrowded KRAS field, avoiding classic cytotoxic-ADC toxicity while adding tumor-selective targeting. And HUTCHMED keeping Greater China rights again signals its now-familiar playbook: license out ex-China, retain commercial control at home.
GSK to license Hutchmed's KRAS-EGFR cancer drug for $110M upfront ↗